Malaysia Biobanks Market Report 2023 to 2030

Malaysia Biobanks Market Analysis

$ 3999

The Malaysia Biobanks Market was valued at $123.38 Mn in 2023 and is predicted to grow at a CAGR of 9% from 2023 to 2030, to $225.54 Mn by 2030. The key drivers of this industry include disease burden, technological advancements, and national genome projects. The industry is primarily dominated by players such as Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

ID: IN10MYHS058 CATEGORY: Healthcare Services GEOGRAPHY: Malaysia AUTHOR: Aashwi Mehta

Buy Now

Malaysia Biobanks Market Executive Summary

The Malaysia Biobanks Market was valued at $123.38 Mn in 2023 and is predicted to grow at a CAGR of 9% from 2023 to 2030, to $225.54 Mn by 2030.

A biobank is a carefully curated collection of primarily human biological samples and associated data, systematically organized for research purposes. These facilities are pivotal in medical research, aiding diverse studies such as genomics and personalized medicine. Each biobank collects samples and data tailored to its specific research goals. For example, some focus on diseases like cancer, while others gather samples and data from specific demographics or geographic regions.

The Malaysian Genome and Vaccine Institute plans to sequence 10,000 genomes and analyze the data for clinical relevance by 2026. This aligns with the Malaysia Precision Medicine Initiative, launched in 2020 by the Academy of Sciences Malaysia, which aims to analyze 10,000 human samples over 10 years, focusing on the country's diverse genetic variations. The market is driven by significant factors like disease burden, technological advancements, and national genome projects. However, time-consuming sample acquisitions, limited public awareness, and logistical challenges restrict the growth and potential of the market.

Prominent players in this field include Thermo Fisher Scientific, Merck KGaA, QIAGEN, and Tecan Group among others.

Malaysia Biobanks Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Disease Burden: Noncommunicable diseases (NCDs) account for about 72% of Malaysia's disease burden. This high prevalence drives the biobank market by underscoring the need for extensive research and data collection to better understand and address these widespread conditions.

Technological Advancements: Advancements in genomic research and biobanking technologies improve the efficiency and functionality of biobanks. This progress stimulates the growth of the biobank market in Malaysia by making biobanks more effective and attractive for research and clinical applications.

National Genome Projects: Projects such as the Malaysian Genome and Vaccine Institute's sequencing effort and the Malaysia Precision Medicine Initiative, which emphasize large-scale genomic data collection and analysis, drive the expansion of the biobank market in Malaysia by creating significant demand for comprehensive biological data and advanced biobanking infrastructure.

Market Restraints

Time-consuming Sample Acquisition: The acquisition of bio-specimen samples is frequently a lengthy and intricate process, requiring strict protocols and specific patient eligibility criteria. This complexity slows down biobank operations and diminishes the efficiency of sample collection, which is essential for effective research and clinical use. As a result, it poses a restraint on the biobank market in Malaysia by hindering timely and efficient data collection.

Limited Public Awareness: A lack of public awareness about the benefits and significance of biobanks can lead to reduced participation and fewer sample donations. This limited understanding acts as a market restraint for the biobank sector in Malaysia, impeding the growth and effectiveness of biobank initiatives.

Logistical Challenges: Managing the collection, storage, and handling of extensive biological samples and data is often complex and requires significant resources. This complexity and resource demand act as a restraint on the biobank market in Malaysia, making it challenging to efficiently operate and scale biobank facilities.

Regulatory Landscape and Reimbursement Scenario

Malaysia lacks specific biobanking laws and instead relies on broader regulations, such as the Human Tissue Act 1974 and the Personal Data Protection Act 2010 (PDPA), which offer some legal context for managing human biological samples and personal data. The Malaysian Guidelines on the Use of Human Biological Samples for Research, issued by the National Committee for Clinical Research, act as a non-binding framework. They stress the importance of informed consent and ethical handling of biological materials but do not enforce legal requirements.

Competitive Landscape

Key Players

Here are some of the major key players in the Malaysia Biobanks Market:

Thermo Fisher Scientific
Merck KGaA
QIAGEN
Tecan Group
Becton, Dickinson and Company
Beckman Coulter
Avantor
Promega Corporation
Hamilton Company
Greiner Bio-One

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Malaysia Biobanks Market Segmentation

By Product and Service

Equipment
Consumables
Services

By Sample Type

Blood Products
Human Tissues
Nucleic Acids
Others

By Application

Regenerative Medicine
Life Science Research
Clinical Research
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.